Skip to main content
Fig. 5 | BMC Neurology

Fig. 5

From: Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

Fig. 5

Cumulative probability of (a) relapse, (b) 24-week–confirmed disability worsening, and (c) 24-week–confirmed disability improvement over 2 years. Cumulative probabilities are based on Kaplan-Meier analysis or the Cox proportional-hazards model. Solid line shows the estimated cumulative probability; dashed lines show the 95% CI. Relapses in the year prior to starting natalizumab were reported by the patient. On-treatment relapses were reported by the physician. For disability outcomes, time point listed is for onset of EDSS increase or decrease, which was then confirmed 24 weeks later. CI = confidence interval; EDSS = Expanded Disability Status Scale

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us